New Research Idiopathic Membranous Nephropathy Treatment Market - Clinical and pathological features | Technology & Innovation, Types, Structure, and Mechanism of Action by 2027
Global Idiopathic Membranous Nephropathy Treatment market analysis
Overview
Membranous nephropathy develops as the blood vessels in the kidney's filters (nephrons) become weakened. Proteinuria, or the leakage of proteins in the urine as a result of thickening of the blood vessel walls, increases the risk of kidney failure. There is no particular medication for the disorder, but it can be managed if administered properly. Nausea, swelling of the legs, elevated cholesterol, weight gain, low appetite, and acute and chronic kidney failure are some of the signs. Main and secondary membranous nephropathy are the two forms of membranous nephropathy. Primary membranous nephropathy develops as the body's antibodies destroy healthy cells, while secondary membranous nephropathy develops as a result of syphilis, hepatitis C, hepatitis B, internalization of drugs such as cancers, NSAIDs, gold salts, and other causes.
Get Sample PDF Including COVID-19 Impact Analysis: https://www.coherentmarketinsights.com/insight/request-pdf/3383
Drivers
Leading pharmaceutical companies are developing medicines to treat idiopathic membranous nephropathy. During the projected period, the global idiopathic membranous nephropathy treatment market is expected to benefit from increased research and development activities related to newer treatment options. Novartis International AG has a potential drug in phase II clinical trials called LNP023. The research will be finished in June 2021. Patients with idiopathic membranous nephropathy are being screened for the drug.
Furthermore, the NIAID (National Institute of Allergy and Infectious Diseases), the Immune Tolerance Network, and GlaxoSmithline are collaborating to better understand the effects of belimumab and rituximab combined treatment on patients with idiopathic membranous nephropathy. The phase II research began in December 2019 and will conclude in February 2025.
As per the New England Journal of Medicine, a clinical trial comparing the effectiveness of rituximab and cyclosporine on patients with membranous nephropathy found that 60 percent of the patients responded positively to the rituximab drug. The other 40% of patients did not respond to the medication in any way. As a result, alternative immunosuppressive treatments for a small number of patients with idiopathic membranous nephropathy who are immune to rituximab therapy have more potential. During the forecast period, the high occurrence of idiopathic membranous nephropathy is expected to drive growth of the global idiopathic membranous nephropathy treatment market.
Restraints
Some side effects have been identified in relation with the medications used for idiopathic membranous nephropathy, as per the American Society of Nephrology's journal from 2012. Some of the side effects include osteoporosis, hyperglycemia, secondary diabetes, infertility, and teratogenic effects throughout birth. Rituximab is yet to be approved by the US Food and Drug Administration for nephropathy. It has, however, been approved for the treatment of dermatomyositis, rheumatoid arthritis, vasculitis, and lupus. During the forecast period, these factors are expected to restrain the global idiopathic membranous nephropathy treatment market's development.
Tailored Information as per niche requirement:
LIMITED TIME OFFER - Hurry Up!
Exclusive offer!!! Purchase the report at a discounted rate!!!
Get Discount For Buyers UPTO 30% OFF On Any Research Report
Buy Now with Discount for Premium Report 2021: https://www.coherentmarketinsights.com/promo/buynow/3383
Regional Analysis
Due to the high prevalence of idiopathic membranous nephropathy in the area, North America is projected to dominate the global idiopathic membranous nephropathy industry. As per the American Society of Nephrology's clinical journal, idiopathic membranous nephropathy affects about 12 million individuals in North America each year between the ages of 50 and 60. As per Biomedical Research International, idiopathic membranous nephropathy is common in North America, Europe, and Asia Pacific.
The majority of suppliers, such as Mylan Pharmaceutical ltd., Bristol-Myers Squibb Company, Merck & Co Inc., and Baxter Healthcare Corporation, are based in the U.S. As a result, the global idiopathic membranous nephropathy treatment market is projected to expand over the forecast period due to the launch of current as well as new treatment options in North America.
Special Requirements?
We value your investment and offer customization as per your requirements.
Share your precise requirements @ https://www.coherentmarketinsights.com/insight/request-customization/3383
Key Players
Major companies contributing in the global idiopathic membranous nephropathy treatment market include Merck and Co Inc., Bristol – Myers Squibb Company, Astellas Pharma Inc., Aspen Global Inc., Sigma Aldrich Corporation, Pfizer Inc. Roche, Baxter Healthcare Corporation, Novartis International AG, and Mylan Pharmaceutical ltd.
Market Segmentation
According to class of the drug:
- Immunosuppressing Agents
- Cyclophosphamide
- Synthetic Adrenocorticotropic Hormone Analogue
- Chlorambucil
- Cyclic Peptides
- Alkylating Agents
- Tacrolimus
- Mycophenolate Mofetil
- Rituximab
- Others
According to the distribution channel:
- Hospital pharmacy
- Online Pharmacy
- Retail pharmacy
According to the region:
- North America
- Latin America
- Europe
- Middle East
- Asia Pacific
- Africa
Other Related News:
About Us:
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
To know more about us, please visit our website – www.coherentmarketinsights.com
Contact:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837
Editor Details
-
Company:
- Coherent Market Insights
-
Name:
- Nirav Gokani
- Email:
-
Telephone:
- +918849480752
- Website:
